GlassScriptPhysician profile
Douglas C Phillips
NPI 1396740882
$11,495.11
in general payments reported to CMS, 2019-2025
41 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,012 · 2020: $1,991 · 2021: $2,267 · 2022: $1,499 · 2023: $847 · 2024: $1,273 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,726.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,914.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,325.22 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $907.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $860.38 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $628.33 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $590.64 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $478.68 | 2019-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.84 | 2019-2025 | Jardiance |
| Pfizer INC. | $396.68 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $372.83 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $336.12 | 2023-2025 | Nuedexta, Rexulti |
| Merck Sharp & Dohme LLC | $322.27 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $316.77 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $300.83 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $232.17 | 2019-2024 | Livalo, Seglentis |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.